Science Corporation implants vision chip in first Stargardt patient

Science Corporation has implanted its vision-restoring chip PRIMA into its first patient with Stargardt disease — a condition doctors currently consider incurable — and the patient read a word during his second rehabilitation session. CEO Max Hodak announced the milestone on stage at TechCrunch Disrupt. The implant took place in May at Sydney Eye Hospital in Australia, as part of the company's ongoing trial.

That matters because Stargardt disease affects roughly 150,000 people worldwide, destroying the central vision they use to read, recognize faces and navigate daily life. Until now, no approved therapy has been able to restore what the disease takes away. The takeaway: a commercial retinal prosthesis is now being stretched beyond its original indication, and it's showing early results.

What is PRIMA and how does it work?

PRIMA is a two millimeter by two millimeter chip that surgeons place at the back of the eye, exactly where the eye's light-sensing cells have degenerated. The procedure takes about an hour. Patients then wear camera-equipped glasses that transmit a view of the world to the chip, which acts like a set of artificial photoreceptors.

The device already has commercial approval in Europe for patients who've lost their sight to geographic atrophy, an advanced form of age-related macular degeneration. Science Corporation believes the same approach can treat multiple diseases, including Stargardt.

The mechanism matters here. Stargardt affects the outer retina, killing the light-sensing cells, but it can spare the inner retina — the part that passes visual signals on to the brain. PRIMA effectively replaces the dead cells and reactivates that surviving signal path. Hodak put it plainly: "That's all vision is to the brain, and so if you can get the optic nerve to signal the rest of the brain correctly, then you can provide vision to it."

What did the first patient actually see?

The results so far are modest but concrete. During the patient's first rehabilitation session, he saw a letter. During the second session, he was able to read a word.

Hodak was frank about the limits. The implant's field of view is tiny — "it's like looking through a straw," he said — and the image is black and white rather than color. But what's there is clear. "It's high-contrast sharp, and so they can see a couple letters at a time," Hodak said.

The next engineering challenge is size and resolution. A bigger implant has to handle the curvature of the eye, and smaller electrodes would get closer to natural levels of detail. Hodak said the path forward is already mapped: "There's a next generation that's being worked on that'll be in humans in the next year, and over the next five years, I think we'll be able to get pretty close to native acuity."

The takeaway: this is a working proof of concept, not a cure — but it's moving fast on a published timeline.

Why is a brain implant company working on eyes?

Hodak co-founded Neuralink and served as its president before leaving to found Science Corporation in 2021. On stage, he framed the retinal work as part of a much bigger bet on brain-computer interfaces.

"The retina is part of the central nervous system," Hodak said. "We consider cochlear implants, retinal prostheses, motor prostheses, these are all different types of BCIs."

In other words, Science Corporation doesn't see BCIs as just a way to control computers with your thoughts. It sees a whole family of medical devices that connect electronics to the nervous system. Vision restoration is the commercially sensible first step — it proves the methods work while building a sustainable business, according to the company.

The company's flagship BCI design differs from Neuralink's. Science Corporation has previously said its sensor will be implanted inside the skull and rest on top of the brain, rather than being inserted directly into brain tissue.

What conditions come next?

Hodak hinted at a pipeline beyond ophthalmology. The company's first clinical indication for the BCI — which hasn't been announced publicly — is, in his words, "a neurodegenerative disease that everybody's heard of."

He also named stroke as a target. The logic: if a stroke kills part of the brain, and you can connect two areas in the deep brain, you could effectively "add new cortical areas, just like adding new brain areas entirely — something simply not possible with conventional electrodes," Hodak said. The company has also said the device could help monitor neurological activity in patients with brain tumors.

The long-term goal is more ambitious still. "The long-term mission of the company is to understand how the brain creates the mind and to learn to build engineered brains," Hodak said.

Who is this actually for?

Hodak's market theory is that BCI adoption won't come from enthusiasts but from aging bodies. Science Corporation isn't designing for "healthy 40-year-olds," he said, but it believes people will eventually need some kind of BCI by the age of 60 or 70.

"We want to figure out how do we extend not just lifespan but health span," Hodak said.

That framing positions the company at the intersection of two large markets: degenerative disease treatment and the medical needs of an aging population. For now, the proof rests on a two-millimeter chip in one patient's eye — and on whether a next-generation device can reach human trials within the year, as Hodak promised on stage.